Description
Nicergoline is a kind of ergot derivative, used to treat Alzheimer’s disease and other vascular diseases, originally researched by Pfizer Pharmaceuticals. Since its successful development in the 1960s, it has been registered and used in more than 50 countries. By 2020, Nicergoline has been included in China’s Class B medical insurance, and there are already several manufacturers in the Chinese market, among which Kunshan Longdeng Ruidi Pharmaceutical Co., Ltd. has the most market share.
According to CRI’s market research, the sales value of Nicergoline in the Chinese market has increased year by year from 2016 to 2020. Among them, the growth in 2019 was the most obvious. The sales value of Nicergoline increased from CNY138 million in 2018 to CNY190 million in 2019, with an annual growth rate of 37.57%. In 2020, the sales value of Nicergoline in the Chinese market is CNY237 million, and the CAGR from 2016 to 2020 is 16.6%.
CRI expects that with the increase in the number of patients with Alzheimer’s disease, the sales value of Nicergoline in the Chinese market will continue to grow from 2021 to 2025. By 2020, the incidence of Alzheimer’s disease in the elderly over 65 years old in China was 4%-6%, and the aging degree in China will continue to increase in the future, which will cause the number of patients with Alzheimer’s disease to continue to increase. Therefore, sales volume and sales value in Nicergoline will also continue to increase.
Topics Covered:
- -The impact of COVID-19 on China’s Nicergoline market
- – Sales value of China’s Nicergoline 2016-2020
- – Competitive landscape of China’s Nicergoline market
- – Prices of Nicergoline in China
- – Prices of Nicergoline in China by regions and manufacturers
- – Analysis on factors affecting the development of China’s Nicergoline market
- – Prospect of China’s Nicergoline market from 2021 to 2025
